ReCor Medical Completes REDUCE Pilot Clinical Study of Its PARADISE™ Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension

Published: May 14, 2012

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with ‘resistant’ hypertension (“HTN”), a major risk factor for cardiovascular disease.

Back to news